Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | IL1RN | P18510 | 1/20 | 0.47 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.46 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35185 | 0.83 | MEN1 (0.65) | SMN1; SMN2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL29399627 | 0.83 | MEN1 (0.65) | SMN1; SMN2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL10722385 | 0.81 | MAPT (0.54) | SMN1; SMN2ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL3715136 | 0.80 | KMT2A (0.58) | SMN1; SMN2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL14221053 | 0.79 | F2 (0.56) | SMN1; SMN2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL20790417 | 0.79 | LMNA (0.52) | SMN1; SMN2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL11647890 | 0.79 | ALDH1A1 (0.47) | SMN1; SMN2ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL8241614 | 0.78 | ALDH1A1 (0.55) | SMN1; SMN2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL17275120 | 0.78 | F2 (0.55) | SMN1; SMN2F2PRSS1PRSS2PRSS3 | |
| SCHEMBL15953453 | 0.77 | MAPK1 (0.69) | SMN1; SMN2ALDH1A1LMNAHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-10899746-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2021-01-26 | — | — | US | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | CYTOKINETICS, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| EP-1831198-B1 | PYRIDINE CARBOXAMIDE DERIVATIVES FOR USE AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| EP-0494140-A4 | DIBENZOFURANCARBOXAMIDES | — | 1992-09-02 | — | — | EP | disclosed |
| EP-0494140-A1 | DIBENZOFURANCARBOXAMIDES | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1992-07-15 | — | — | EP | disclosed |
| WO-1991004738-A1 | DIBENZOFURANCARBOXAMIDES | RORER INTERNATIONAL (HOLDINGS), INC. (US) | 1991-04-18 | — | — | WO | disclosed |
| US-4959485-A | 5-HT3 ANTAGONISTS | RORER PHARMACEUTICAL CORPORATION (US) | 1990-09-25 | — | — | US | disclosed |
| WO-1989010364-A1 | DIBENZOFURANCARBOXAMIDES | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-11-02 | — | — | WO | disclosed |
| EP-0339950-A2 | Dibenzofurancarboxamides, their use as pharmaceutical agents, a composition containing the same, and a process for the preparation thereof | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-11-02 | — | — | EP | disclosed |
| US-4863921-A | Dibenzofurancarboxamides and their pharmaceutical compositions and methods | RORER PHARMACEUTICAL CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | SMN1; SMN2 126/4885F2 4577/4885PRSS1 2473/4885 |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | SMN1; SMN2 126/4885F2 4577/4885PRSS1 2473/4885 |
| US-20090118261-A1 | QUINAZOLINONE DERIVATIVES AND THEIR USE AS B-RAF INHIBITORS | BRAF, RAF1, ARAF | SMN1; SMN2 4771/4885F2 1127/4885PRSS1 2530/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | SMN1; SMN2 126/4885F2 4577/4885PRSS1 2473/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | SMN1; SMN2 126/4885F2 4577/4885PRSS1 2473/4885 |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | SMN1; SMN2 126/4885F2 4577/4885PRSS1 2473/4885 |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | TNNI3, TNNT2, TNNC1 | SMN1; SMN2 202/4885F2 2577/4885PRSS1 1514/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | SMN1; SMN2 126/4885F2 4577/4885PRSS1 2473/4885 |
| US-10899746-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | SMN1; SMN2 126/4885F2 4577/4885PRSS1 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.